Pharmacotherapy in Interstitial Cystitis/ Painful Bladder Syndrome

Authors : Merve Denizaltı, N. Tuğba Kandilci

Pages : 867-880

Doi:10.55262/fabadeczacilik.1798434

View : 41 | Download : 82

Publication Date : 2025-10-30

Article Type : Review Paper

Abstract :Interstitial cystitis/ Painful bladder syndrome is a chronic disease characterized by suprapubic pain associated with bladder filling, accompanied by an overactive detrusor and inflammation of the bladder. Although the etiology and pathophysiology of this disease are not precisely known, many pathophysiological theories have been proposed, such as the glycosaminoglycan theory, altered permeability, neural regulation, mast cell and neuroendocrine theories. Different treatment methods have been developed based on these theories. The developed pharmacotherapies can be classified as conservative treatment, oral treatment, intravesical treatment and current treatment methods. Agents used in oral treatment include pentosan polysulfate, tricyclic antidepressants, histamine receptor antagonists, immunosuppressants and AQX-1125 (Rosiptor); while agents used in intravesical therapy include dimethyl sulfoxide, lidocaine, heparin and pentosan polysulfate, chondroitin sulfate and hyaluronic acid, and bacillus calmette-guerin. The use of botulinum toxin A (BTX-A) has also been approved. Finally, current treatment methods include phosphodiesterase-5 inhibitors, monoclonal antibodies, cannabinoids, and liposome use. The goal of most treatments is to control symptoms.
Keywords : İnterstitial sistit/ Ağrılı mesane sendromu, inflamasyon, konservatif tedavi, oral tedavi, intravezikal tedavi

ORIGINAL ARTICLE URL